Rise of Genomics in Clinical Trials - 10

A Proper MATCH:
New NGS Method Up to
Snuff for Tumor Analysis in
NCI-MATCH Clinical Trial

10

| ClinicalOMICs.com

grouped based on their mutations and not their
specific cancer-with the hope that treating
these cancers on the basis of their mutational
profile will be more effective. The program set
up by NCI is called the Molecular Analysis for
Therapy Choice (NCI-MATCH) and is looking to
examine tumor samples from approximately
6,000 patients.

ADDITIONAL CONTENT

Integrate NGS Data into
Your Clinical Trials
Learn how the DNAnexus Clinical Trials Solution
can improve trial results, while reducing the time
and cost of clinical development.
Learn more

The goals are ambitious, and complicated
by the concerns expressed by many
researchers about the complexity, accuracy,

Natali_Mis / Getty Images

I

n the fight against cancer, scientists and clinicians have looked toward novel approaches
that provide a more comprehensive understanding of the molecular mechanisms that drive the
disease-all with the hope of uncovering new
therapies that afford many patients a better
quality of care. To that end, in August of 2015,
the National Cancer Institute (NCI) began enrolling patients into a unique initiative that looked
to analyze cancer patients' tumors for actionable
mutations for which a targeted therapy already
exists. The unique aspect is that patients were

https://www.dnanexus.com/clinicaltrials?utm_source=ClinicalOMICS&utm_medium=ebook&utm_campaign=clinical_trials http://www.clinicalomics.com

Rise of Genomics in Clinical Trials

Table of Contents for the Digital Edition of Rise of Genomics in Clinical Trials